tert-Butyl ((2S,3S)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)carbamate

Catalog No. :
ACGIPB420
CAS No. :
110312-83-9
Molecular Formula :
C9H16N2O4
Molecular Weight :
216.24

IUPAC Name:tert-butyl ((2S,3S)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)carbamate

tert-Butyl ((2S,3S)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg98%$817.00Login to see priceInquiryInquiry
1g98%$2043.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl ((2S,3S)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)carbamate
IUPAC Nametert-butyl ((2S,3S)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)carbamate
MDL No.MFCD30267373
Molecular FormulaC9H16N2O4
Molecular Weight216.24
SMILESCC(C)(C)OC(=O)N[C@@H]1C(=O)N[C@@H]1CO
InChI KeyJGCFOKHULWJGSK-RITPCOANSA-N
Synonymtert-butyl((2S,3S)-2-(hydroxymethyl)-4-oxo-1l2-azetidin-3-yl)carbamate;tert-butyl [(2S,3S)-2-(hydroxymethyl)-4-oxoazetidin-3-yl]carbamate;tert-butyl ((2S)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)carbamate;tert-butyl ((2S)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)carbamate(WXC01546);Carbamic acid, [(2S,3S)-2-(hydroxymethyl)-4-oxo-3-azetidinyl]-, 1,1-dimethylethyl ester (9CI)
CAS No.110312-83-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACGIPB420 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACGIPB420 route product structure diagram
    ACGIPB420110312-83-9
Inquiry

2. ACGIPB420 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACGIPB420 route product structure diagram
    ACGIPB420110312-83-9
Inquiry

Comments (0)